Try
Alkermes plc Ordinary Shares
ALKSUnited States
54 filed reports · 523 financial concepts · 1 earnings calls · 2 media appearances
Filed reports
54 reports · Mar 2017 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 9 operating metrics, 124 guidance figures, 57 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 30 | 5,571 | Mar 2017 to Jun 2026 |
| Current · 8-KSEC EDGAR | 11 | 126 | Sep 2017 to Dec 2020 |
| Annual · 10-KSEC EDGAR | 10 | 4,239 | Dec 2017 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 3 | 3 | Dec 2020 to Dec 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 28, 2026 | 435 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 3 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 272 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 868 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 11 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 28, 2025 | 293 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 29, 2025 | 186 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 189 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 12, 2025 | 437 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 24, 2024 | 202 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Jul 24, 2024 | 172 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 1, 2024 | 209 | Open |
Financial data
523 concepts · 9,939 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial496 concepts · 9,260 facts · Dec 2015 to Jun 2026
- Amortized Cost80 · Dec 2016 to Mar 2024
- Gross Unrealized Losses, Less than One Year80 · Dec 2016 to Mar 2024
- Gross Unrealized Gains65 · Dec 2016 to Mar 2024
- Cash and cash equivalents at carrying value54 · Dec 2015 to Jun 2026
- Comprehensive income net of tax53 · Dec 2015 to Jun 2026
- Costs and expenses53 · Dec 2015 to Jun 2026
- Deferred income tax expense benefit53 · Dec 2015 to Jun 2026
- Depreciation depletion and amortization53 · Dec 2015 to Jun 2026
- Income tax expense benefit53 · Dec 2015 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities53 · Dec 2015 to Jun 2026
- Increase decrease in inventories53 · Dec 2015 to Jun 2026
- Increase decrease in other operating liabilities53 · Dec 2015 to Jun 2026
- Increase decrease in receivables53 · Dec 2015 to Jun 2026
- Investment income interest53 · Dec 2015 to Jun 2026
- Noncash or part noncash acquisition value of liabilities assumed153 · Dec 2015 to Jun 2026
- Nonoperating income expense53 · Dec 2015 to Jun 2026
- Operating income loss53 · Dec 2015 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax53 · Dec 2015 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period tax53 · Dec 2015 to Jun 2026
- Other nonoperating income expense53 · Dec 2015 to Jun 2026
- Payments related to tax withholding for share based compensation53 · Dec 2015 to Jun 2026
- Payments to acquire marketable securities53 · Dec 2015 to Jun 2026
- Payments to acquire property plant and equipment53 · Dec 2015 to Jun 2026
- Proceeds from issuance of shares under incentive and share based compensation plans including stock options53 · Dec 2015 to Jun 2026
Product7 concepts · 423 facts · Dec 2016 to Jun 2026
- Revenue383 · Dec 2016 to Jun 2026
- Accounts Payable17 · Dec 2022 to Mar 2026
- Biogen7 · Dec 2019 to Dec 2025
- Revenue (excluding assessed tax)7 · Nov 2017 to Sep 2019
- VIVITROL6 · Jun 2020 to Dec 2020
- Cost of goods and services sold (US GAAP)2 · Mar 2017 to Mar 2018
- Contract with customer liability revenue recognized1 · Sep 2018
Guidance7 concepts · 126 facts · Oct 2017 to Feb 2021
- Net Income Guidance22 · Oct 2017 to Feb 2021
- Revenue Guidance22 · Oct 2017 to Feb 2021
- Capital Expenditures Guidance20 · Oct 2017 to Feb 2021
- EPS (Diluted) Guidance20 · Oct 2017 to Feb 2021
- Net Income Guidance (Adjusted (non-GAAP))20 · Oct 2017 to Feb 2021
- EPS (Diluted) Guidance (Adjusted (non-GAAP))16 · Feb 2018 to Feb 2021
- EPS (Diluted) Guidance (basic; Adjusted (non-GAAP))6 · Oct 2018 to Oct 2019
Geography12 concepts · 121 facts · Dec 2015 to Mar 2026
- Revenue40 · Dec 2015 to Dec 2025
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments24 · Dec 2015 to Dec 2020
- Total Current Assets18 · Dec 2016 to Dec 2022
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest16 · Dec 2019 to Dec 2025
- Cash and Equivalents6 · Dec 2023 to Dec 2025
- Property, Plant & Equipment, Net6 · Dec 2023 to Dec 2025
- Deferred income tax expense benefit4 · Dec 2016 to Dec 2019
- Deferred foreign income tax expense benefit2 · Dec 2018 to Dec 2019
- Pretax Income2 · Dec 2021
- Current foreign tax expense benefit1 · Dec 2021
- EU1 · Dec 2022
- Statutory tax rate1 · Mar 2026
KPI1 concepts · 9 facts · Dec 2025 to Jun 2026
- Average Selling Price per Unit YoY Change9 · Dec 2025 to Jun 2026
Segments
544 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis15 members · 401 facts
- Vivitrol50 · Dec 2016 to Jun 2026
- Manufactured Product And Royalty47 · Dec 2016 to Jun 2026
- Product47 · Dec 2016 to Jun 2026
- Research And Development44 · Dec 2016 to Sep 2025
- Manufacturing Revenue41 · Dec 2017 to Jun 2026
- Royalty41 · Dec 2017 to Jun 2026
- Aristada And Aristada Initio34 · Dec 2018 to Jun 2026
- LYBALVI23 · Dec 2021 to Jun 2026
- License22 · Dec 2017 to Dec 2022
- Aristada16 · Dec 2016 to Dec 2020
- State usmedicaid rebates10 · Dec 2023 to Mar 2026
- Aristada Or Aristada Initio10 · Dec 2017 to Sep 2020
- State medicaid rebates7 · Dec 2022 to Dec 2025
- Vumerity7 · Dec 2019 to Dec 2025
- LUMRYZ2 · Mar 2026 to Jun 2026
Statement geographicalsrt:StatementGeographicalAxis6 members · 83 facts
- IE29 · Dec 2016 to Mar 2026
- US22 · Dec 2016 to Dec 2025
- Foreign Country Excluding Specified Country18 · Dec 2016 to Dec 2025
- Ie6 · Dec 2023 to Dec 2025
- Us6 · Dec 2023 to Dec 2025
- European Union2 · Dec 2022
Statement geographicalus-gaap:StatementGeographicalAxis6 members · 38 facts
- Ie8 · Dec 2016 to Dec 2022
- Us8 · Dec 2016 to Dec 2022
- Foreign Country Excluding Specified Country6 · Dec 2015 to Dec 2017
- IE6 · Dec 2015 to Dec 2017
- US6 · Dec 2015 to Dec 2017
- Foreign country excluding specified country4 · Dec 2016 to Dec 2019
Product or serviceus-gaap:ProductOrServiceAxis12 members · 22 facts
- Research and development4 · Nov 2017 to Sep 2019
- Manufactured Product And Royalty4 · Mar 2017 to Mar 2018
- Aristada2 · Mar 2017 to Mar 2018
- Product2 · Mar 2017 to Mar 2018
- Research And Development2 · Mar 2017 to Mar 2018
- Vivitrol2 · Mar 2017 to Mar 2018
- Clinical supply1 · Nov 2017
- Research and development revenue1 · Nov 2017
- Clinical Supply1 · Mar 2018
- License1 · Mar 2018
- Research And Development Revenue1 · Mar 2018
- License1 · Nov 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary119 claims from 11 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary163 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes16 claims from 1 reports · Dec 2025
- Risk factors83 risks from 2 annual reports · 2024 to 2025
Earnings calls
1 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 28, 2026
Executive media
2 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances2 · Jul 2023 to Jan 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.